The single center, prospective clinical trial of low-dose Decitabine in the treatment of MDS/AML early relapse after allogeneic hematopoietic stem cell transplantation

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-17012796

Enrollment

Unknown

Registered

2017-09-26

Start date

2017-10-01

Completion date

Unknown

Last updated

2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myeloid leukemia/Myelodysplastic syndrom

Interventions

low-dose decitabine:decitabine 5mg/m2 d1-5

Eligibility

Sex/Gender

All

Age

No minimum to 60 Years

Inclusion criteria

Inclusion criteria: 1. MDS/AML early relapse after allogeneic hematopoietic stem cell transplantation; 2. Age 60, expected survival > 3 months; 3. No serious organ dysfunction; 4. Informed consent.

Exclusion criteria

Exclusion criteria: 1. With serious organ dysfunction; 2. Combined with other cancer need treatment; 3. Presence of clinical signs of brain dysfunction or severe mental illness can not comply with the study protocol; 4. Can not guarantee the completion of the treatment plan and the necessary follow-up observation.

Design outcomes

Primary

Measure	Time frame
Complete remission;	—

Countries

China

Contacts

Public ContactPeiyan Kong

Department of Hematology, Xinqiao Hospital

peiyankong@aliyun.com+86 13228685528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026